labor%20induction
LABOR INDUCTION
Labor induction is when an external agent is employed to stimulate contractions before the onset of spontaneous labor.
Labor augmentation uses the same techniques as labor induction but uterine contractions (frequency, duration and strength) are enhanced once labor has started.
Labor induction is generally indicated when the benefits of delivery outweigh the risks of continuing the pregnancy.
Women at 42 weeks of gestation who chose not to undergo labor induction should be monitored more often with at least twice-weekly assessment of fetal well-being (cardiotocography & estimation of maximum amniotic pool depth by ultrasound).

Patient Education

  • Patient should be informed that most women will go into spontaneous labor by 42 weeks
  • She should be made aware of the risks involved should pregnancy continue by >42 weeks and offered options such as membrane sweeping, expectant management and labor induction between 41 and 42 weeks
  • The following should be explained to the patient:
    • Reason for the induction
    • Time, place and method of the induction
    • Risks and benefits of the proposed method of induction
    • Possibility that induced labor is likely to be more painful than spontaneous labor and the availability of pain relief options
    • Other options should patient decide not to undergo induction
    • That induction may fail and what would be the next step should this happen
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Children with high dental anxiety are more likely to develop dental diseases, which, in turn, negatively affect the family’s quality of life, a recent study has found.
2 days ago
Exposure to corticosteroids in patients with autoimmune hepatitis (AIH) appears to contribute to increased risks of cataract, diabetes and bone fractures, a study has found. Notably, the fracture risk is elevated at low doses, while the risk of adverse events overall is dose-dependent and is reversible.
14 Nov 2019
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
4 days ago
Supplementation with oral nano vitamin D appears to moderate disease activity and severity grade of patients with active ulcerative colitis (UC), suggests a study, adding that this association is more evident in those achieving a target vitamin D level of 40 ng/mL.